

Sara Lopez-Tarruella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3643990/publications.pdf>

Version: 2024-02-01

70
papers

8,498
citations

136740

32
h-index

110170

64
g-index

72
all docs

72
docs citations

72
times ranked

10423
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Trastuzumab in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 1273-1283.	13.9	2,254
2	Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	13.9	1,472
3	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1873.	3.8	531
4	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2 ⁻ , Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478
5	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	5.1	451
6	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	13.9	363
7	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€²298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , The, 2019, 393, 1440-1452.	6.3	260
8	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5351-5361.	3.2	185
9	Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. <i>Lancet Oncology</i> , The, 2007, 8, 219-225.	5.1	181
10	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
11	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 60-72.	5.1	161
12	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancerâ€”The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	0.8	153
13	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
14	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
15	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1045-1052.	0.8	108
16	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657.	3.2	108
17	Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. <i>Cancer Treatment Reviews</i> , 2009, 35, 335-339.	3.4	94
18	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS. <i>Gut</i> , 2015, 64, 111-120.	6.1	93

#	ARTICLE	IF	CITATIONS
19	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , 2018, 24, 1845-1852.	3.2	84
20	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3995-4003.	3.2	82
21	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018, 24, 5820-5829.	3.2	82
22	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , 2013, 15, R105.	2.2	80
23	Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 371-382.	1.1	73
24	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. <i>Cancer</i> , 2019, 125, 3974-3984.	2.0	67
25	Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 127-136.	1.1	66
26	The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm. <i>Clinical Cancer Research</i> , 2007, 13, 6921-6925.	3.2	52
27	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	51
28	Trastuzumab Associated with Successive Cytotoxic Therapies Beyond Disease Progression in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 325-329.	1.1	46
29	Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 903-913.	1.1	41
30	Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer. <i>Oncologist</i> , 2013, 18, 917-923.	1.9	41
31	Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 591-600.	1.1	38
32	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).. <i>Journal of Clinical Oncology</i> , 2016, 34, 500-500.	0.8	32
33	Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 583-593.	1.1	31
34	Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer. <i>Breast Cancer Research</i> , 2009, 11, 204.	2.2	27
35	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 507-515.	1.1	27
36	Neratinib (HKI-272) in the treatment of breast cancer. <i>Future Oncology</i> , 2012, 8, 671-681.	1.1	26

#	ARTICLE	IF	CITATIONS
37	Neratinib for the treatment of HER2-positive early stage breast cancer. Expert Review of Anticancer Therapy, 2017, 17, 669-679.	1.1	22
38	GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain. Oncologist, 2020, 25, e1339-e1345.	1.9	14
39	Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. Scientific Reports, 2021, 11, 7064.	1.6	13
40	Technical Challenges for CTC Implementation in Breast Cancer. Cancers, 2021, 13, 4619.	1.7	13
41	Emerging Therapeutic Options for HER2-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e64-e70.	1.8	13
42	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. Breast Cancer Research and Treatment, 2017, 162, 181-189.	1.1	11
43	Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Tj ETQq1 1 0.784314 rgBT /Over	1.6	11
44	How we treat HR-positive, HER2-negative early breast cancer. Future Oncology, 2022, 18, 1003-1022.	1.1	11
45	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Drugs, 2020, 80, 131-146.	4.9	10
46	Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelial ovarian cancer patients. Long-term single institution experience and literature review. Clinical and Translational Oncology, 2011, 13, 121-132.	1.2	8
47	Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. Breast Care, 2017, 12, 296-302.	0.8	8
48	Endocrine therapy for hormone treatment-naïve advanced breast cancer. Breast, 2016, 28, 161-166.	0.9	7
49	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Future Oncology, 2017, 13, 2137-2149.	1.1	7
50	Unravelling the mystery of the TACT trial. Lancet, The, 2009, 373, 1662-1663.	6.3	5
51	Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. Clinical Breast Cancer, 2016, 16, 364-371.	1.1	5
52	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. Journal of Genetic Counseling, 2018, 27, 854-862.	0.9	5
53	Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. Anti-Cancer Drugs, 2010, 21, S19-S22.	0.7	4
54	Zooming in on the schedule of bone-modifying drugs. Lancet Oncology, The, 2013, 14, 575-576.	5.1	4

#	ARTICLE	IF	CITATIONS
55	Maintenance therapy in breast cancer—many questions remain. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 370-372.	12.5	4
56	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene. <i>Cancer Management and Research</i> , 2018, Volume 10, 4517-4522.	0.9	4
57	Evaluation of a Heredofamilial Cancer Unit in Increasing Family History Collection and Genetic Counseling Referrals Among Spanish Oncologists at a University Hospital. <i>Journal of Genetic Counseling</i> , 2014, 23, 108-113.	0.9	3
58	S-1 versus taxanes for HER2-negative metastatic breast cancer. <i>Lancet Oncology</i> , The, 2016, 17, 11-12.	5.1	3
59	Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer. <i>Mathematics</i> , 2021, 9, 222.	1.1	2
60	DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. <i>Journal of Personalized Medicine</i> , 2021, 11, 792.	1.1	2
61	HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. <i>Cancers</i> , 2022, 14, 512.	1.7	2
62	The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0. <i>Supportive Care in Cancer</i> , 2022, 30, 6745-6754.	1.0	2
63	Optimizing Adjuvant Taxanes in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2334-2336.	0.8	1
64	Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer. <i>Acta Oncol</i> 3gica, 2008, 47, 1584-1589.	0.8	0
65	Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM —El Álamo III— retrospective study. <i>PLoS ONE</i> , 2017, 12, e0184181.	1.1	0
66	Dose escalation of POL6326 in combination with eribulin in HER2-negative relapsed metastatic breast cancer (mBCa) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2548-2548.	0.8	0
67	Simulation modeling approaches to answer clinically relevant questions in breast cancer low-risk populations. <i>Annals of Translational Medicine</i> , 2018, 6, S80-S80.	0.7	0
68	Docetaxel extravasation: a case report. , 2003, 5, 47-48.		0
69	Abstract P1-15-04: Features of HER2+ metastatic patients (pts) from a prospective registry of advanced breast cancer (ABC), GEICAM/2014-03 (RegistEM). <i>Cancer Research</i> , 2022, 82, P1-15-04-P1-15-04.	0.4	0
70	Abstract PD4-08: Breast cancer clinical subtypes in brain metastases patients from a prospective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM). <i>Cancer Research</i> , 2022, 82, PD4-08-PD4-08.	0.4	0